An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1647-1655

  Shukla, Shakti D ^a   Fairbairn, Rory L ^a   Gell, David A ^a   Latham, Roger D ^a   Sohal, Sukhwinder S ^a,b   Walters, Eugene H ^a   O’Toole, Ronan F ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Airway epithelium; NTHi; PAFr antagonist; Platelet activating factor receptor; Pneumococci; WEB 2086

Indexed keywords

APAFANT; CIGARETTE SMOKE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; ANTIINFECTIVE AGENT; AZEPINE DERIVATIVE; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; PROTEIN BINDING; SMOKE; TRIAZOLE DERIVATIVE;

ARTICLE; BACTERIUM ADHERENCE; BINDING SITE; BRONCHUS MUCOSA; COMPUTER MODEL; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; STREPTOCOCCUS PNEUMONIAE; UPREGULATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BRONCHUS; CELL LINE; CHEMISTRY; DRUG EFFECTS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; PATHOGENICITY; PNEUMOCOCCAL INFECTIONS; PROTEIN CONFORMATION; SMOKE; SMOKING;

ANTI-BACTERIAL AGENTS; AZEPINES; BACTERIAL ADHESION; BINDING SITES; BRONCHI; CELL LINE; EPITHELIAL CELLS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR DOCKING SIMULATION; PLATELET MEMBRANE GLYCOPROTEINS; PNEUMOCOCCAL INFECTIONS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SMOKE; SMOKING; STREPTOCOCCUS PNEUMONIAE; TRIAZOLES;

EID: 84982306182     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S108698     Document Type: Article

References (42)

1. WHO. The Top 10 Causes of Death. Geneva: World Health Organization; 2014.
2. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11): 935-939.
3. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? - Report from the obstructive lung disease in northern Sweden studies. Respir Med. 2003;97(2): 115-122.
4. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther. 2010;23(5): 376-383.
5. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342(10): 681-689.
6. Voss M, Wonnenberg B, Honecker A, et al. Cigarette smoke-promoted acquisition of bacterial pathogens in the upper respiratory tract leads to enhanced inflammation in mice. Respir Res. 2015;16(1): 41.
7. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22): 2355-2365.
8. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J. 1997;10(5): 1137-1144.
9. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD.. Int J Chron Obstruct Pulmon Dis. 2012;7: 555-569.
10. Grigg J. The platelet activating factor receptor: a new anti-infective target in respiratory disease? Thorax. 2012;67(9): 840-841.
11. Shukla S, Sohal S, Reid D, Grigg J, Walters E. Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroids. Paper presented at: European Respiratory Society Annual Congress; 2013; Barcelona, Spain.
12. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J. 1992;6(6): 2296-2301.
13. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995;377(6548): 435-438.
14. Swords WE, Buscher BA, Ver Steeg Ii K, et al. Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor. Mol Microbiol. 2000;37(1): 13-27.
15. Shukla SD, Sohal SS, O’Toole RF, Eapen MS, Walters EH. Platelet activating factor receptor: gateway for bacterial chronic airway infection in chronic obstructive pulmonary disease and potential therapeutic target. Expert Rev Respir Med. 2015;9(4): 473-485.
16. Shukla SD, Sohal SS, Mahmood MQ, Reid D, Muller HK, Walters EH. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease.. Int J Chron Obstruct Pulmon Dis. 2014;9: 853-861.
17. Shukla SD, Muller HK, Latham R, Sohal SS, Walters EH. Platelet-activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients. Respirology. 2016;21(3): 504-510.
18. Grigg J, Walters H, Sohal SS, et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. Thorax. 2012;67(10): 908-913.
19. Cellai C, Laurenzana A, Vannucchi AM, et al. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer. 2006;94(11): 1637-1642.
20. Cellai C, Laurenzana A, Vannucchi AM, Della Malva N, Bianchi L, Paoletti F. Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. FASEB J. 2002;16(7): 733-735.
21. Kato M, Imoto K, Miyake H, Oda T, Miyaji S, Nakamura M. Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs. J Pharmacol Sci. 2004;95(4): 435-442.
22. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EE. Nontypeable Haemophilus influenzae adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. Infect Immun. 2006;74(2): 830-838.
23. Adamou JE, Wizemann TM, Barren P, Langermann S. Adherence of Streptococcus pneumoniae to Human Bronchial Epithelial Cells (BEAS-2B). Infection Immun. 1998;66(2): 820-822.
24. Mushtaq N, Ezzati M, Hall L, et al. Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter. J Allergy Clin Immunol. 2011;127(5): 1236-1242.e1232.
25. Latham R, Zhang B, Tristram S. Identifying Haemophilus haemolyticus and Haemophilus influenzae by SYBR Green real-time PCR.. J Microbiol Methods. 2015;112: 67-69.
26. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234(3): 779-815.
27. Zhang J, Yang J, Jang R, Zhang Y. GPCR-I-TASSER: A hybrid approach to G protein-coupled receptor structure modeling and the application to the human genome. Structure. 2015;23(8): 1538-1549.
28. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2): 455-461.
29. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox.. J Cheminform. 2011;3: 33.
30. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model. 1999;17(1): 57-61.
31. Marti-Lliteras P, Lopez-Gomez A, Mauro S, et al. Nontypable Haemophilus influenzae displays a prevalent surface structure molecular pattern in clinical isolates. PLoS One. 2011;6(6): e21133.
32. Swords WE, Ketterer MR, Shao J, Campbell CA, Weiser JN, Apicella MA. Binding of the non-typeable Haemophilus influenzae lipooligosaccharide to the PAF receptor initiates host cell signalling. Cell Microbiol. 2001;3(8): 525-536.
33. Clark SE, Snow J, Li J, Zola TA, Weiser JN. Phosphorylcholine allows for evasion of bactericidal antibody by Haemophilus influenzae. PLoS Pathog. 2012;8(3): e1002521.
34. Weiser JN, Pan N, McGowan KL, Musher D, Martin A, Richards J. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med. 1998;187(4): 631-640.
35. Weiser JN, Shchepetov M, Chong ST. Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae. Infect Immun. 1997;65(3): 943-950.
36. McCrea KW, Xie J, Marrs CF, Gilsdorf JR. Prevalence of genetic differences in phosphorylcholine expression between nontypeable Haemophilus influenzae and Haemophilus haemolyticus.. BMC Microbiol. 2010;10: 286.
37. Weiser JN, Love JM, Moxon ER. The molecular mechanism of phase variation of H. influenzae lipopolysaccharide. Cell. 1989;59(4): 657-665.
38. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006;231(5): 490-504.
39. Fan X, Pericone CD, Lysenko E, Goldfine H, Weiser JN. Multiple mechanisms for choline transport and utilization in Haemophilus influenzae. Mol Microbiol. 2003;50(2): 537-548.
40. Rijneveld AW, Weijer S, Florquin S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis. 2004;189(4): 711-716.
41. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol. 2006;290(1): L194-L199.
42. Ishizuka S, Yamaya M, Suzuki T, et al. Acid exposure stimulates the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells: effects on platelet-activating factor receptor expression. Am J Respir Cell Mol Biol. 2001;24(4): 459-468.